Desquinolinyl Lenvatinib CAS 796848-79-8 Purity >99.0% (HPLC) Lenvatinib Mesylate Intermediate Factory

Short Description:

1-(2-Chloro-4-Hydroxyphenyl)-3-Cyclopropylurea

Synonyms: Desquinolinyl Lenvatinib 

CAS: 796848-79-8

Purity: >99.0% (HPLC) 

Appearance: Off-White to Reddish Brown Solid Powder

Intermediate of Lenvatinib Mesylate CAS 857890-39-2

E-Mail: alvin@ruifuchem.com


Product Detail

Related Products

Product Tags

Description:

Chemical Properties:

Chemical Name 1-(2-Chloro-4-Hydroxyphenyl)-3-Cyclopropylurea
Synonyms Desquinolinyl Lenvatinib; Lenvatinib Impurity 16; Lenvatinib Desquinolinyl Impurity;  Lenvatinib Impurity LFS-A; Lenvatinib Mesylate Intermediate Ⅲ; N-(2-Chloro-4-Hydroxyphenyl)-N'-Cyclopropyl-Urea
CAS Number 796848-79-8
CAT Number RF-PI1972
Stock Status In Stock, Production Scale Up to Tons
Molecular Formula C10H11ClN2O2
Molecular Weight 226.66
Boiling Point 364.6±42.0℃
Density 1.43±0.10 g/cm3
Brand Ruifu Chemical

Specifications:

Item Specifications
Appearance Off-White to Reddish Brown Solid Powder
Purity / Analysis Method >99.0% (HPLC)    
Moisture (K.F) <0.50%
Residue on Ignition <0.20%
Single Impurity <0.50%
Total Impurities <1.00%
Heavy Metals <10ppm
Infrared Spectrum Conforms to Structure
NMR  Conforms to Structure
Test Standard Enterprise Standard
Usage Intermediate of Lenvatinib Mesylate (CAS: 857890-39-2)

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture

Advantages:

1

FAQ:

Application:

1-(2-Chloro-4-Hydroxyphenyl)-3-Cyclopropylurea, also known as Desquinolinyl Lenvatinib, (CAS: 796848-79-8) is an intermediate or impurity of Lenvatinib Mesylate (CAS: 857890-39-2). Desquinolinyl Lenvatinib is a metabolite of Lenvatinib Mesylate which is an orally active inhibitor of multiple receptor tyrosine kinases including VEGF, FGF and SCF receptors. Lenvatinib is an anti-cancer drug for the treatment of certain kinds of thyroid cancer, and potentially for other cancers as well. On February 13, 2015, the US FDA approved anticancer drug Lenvatinib for the treatment of thyroid cancer. Lenvatinib is a multi-target enzyme inhibitor, being capable of inhibiting the VEGFR2 and VEGFR3 (vascular endothelial growth factor receptor). The trade name of Lenvatinib is Lenvima.

  • Write your message here and send it to us